JP2023545722A5 - - Google Patents

Info

Publication number
JP2023545722A5
JP2023545722A5 JP2023521279A JP2023521279A JP2023545722A5 JP 2023545722 A5 JP2023545722 A5 JP 2023545722A5 JP 2023521279 A JP2023521279 A JP 2023521279A JP 2023521279 A JP2023521279 A JP 2023521279A JP 2023545722 A5 JP2023545722 A5 JP 2023545722A5
Authority
JP
Japan
Prior art keywords
tissue
seq
cells
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023521279A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023545722A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/054008 external-priority patent/WO2022076711A2/en
Publication of JP2023545722A publication Critical patent/JP2023545722A/ja
Publication of JP2023545722A5 publication Critical patent/JP2023545722A5/ja
Pending legal-status Critical Current

Links

JP2023521279A 2020-10-07 2021-10-07 遺伝子治療剤の眼送達のためのアデノ随伴ウイルス Pending JP2023545722A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063088982P 2020-10-07 2020-10-07
US63/088,982 2020-10-07
US202163187197P 2021-05-11 2021-05-11
US63/187,197 2021-05-11
PCT/US2021/054008 WO2022076711A2 (en) 2020-10-07 2021-10-07 Adeno-associated viruses for ocular delivery of gene therapy

Publications (2)

Publication Number Publication Date
JP2023545722A JP2023545722A (ja) 2023-10-31
JP2023545722A5 true JP2023545722A5 (enExample) 2024-10-17

Family

ID=78483550

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023521279A Pending JP2023545722A (ja) 2020-10-07 2021-10-07 遺伝子治療剤の眼送達のためのアデノ随伴ウイルス

Country Status (9)

Country Link
US (1) US20230381341A1 (enExample)
EP (1) EP4225777A2 (enExample)
JP (1) JP2023545722A (enExample)
KR (1) KR20230082614A (enExample)
AU (1) AU2021356667A1 (enExample)
CA (1) CA3193697A1 (enExample)
IL (1) IL301647A (enExample)
MX (1) MX2023003699A (enExample)
WO (1) WO2022076711A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023060272A2 (en) * 2021-10-07 2023-04-13 Regenxbio Inc. Recombinant adeno-associated viruses for cns tropic delivery
TW202345913A (zh) 2022-04-06 2023-12-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如凝膠調配物
TW202404651A (zh) 2022-04-06 2024-02-01 美商銳進科斯生物股份有限公司 用於脈絡膜上投與之調配物諸如形成聚集體之調配物
US20260034246A1 (en) * 2022-05-03 2026-02-05 Regenxbio Inc. Vectorized anti-complement antibodies and complement agents and administration thereof
WO2023215807A1 (en) * 2022-05-03 2023-11-09 Regenxbio Inc. VECTORIZED ANTI-TNF-α INHIBITORS FOR OCULAR INDICATIONS
EP4532517A1 (en) * 2022-05-31 2025-04-09 Mount Spec Investments Pty Ltd Modified adeno-associated virus capsid proteins and methods thereof
EP4540270A2 (en) * 2022-06-14 2025-04-23 Vectory B.V. Recombinant aav capsid proteins
US20260055144A1 (en) * 2022-08-24 2026-02-26 Regenxbio Inc. Recombinant adeno-associated viruses and uses thereof
AU2024206221A1 (en) * 2023-01-05 2025-07-03 Emugen Therapeutics Llc Retro-aav and use in treating neurodegenerative diseases
WO2024238853A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Adeno-associated viruses for ocular delivery of gene therapy
WO2024238867A1 (en) * 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
TW202548025A (zh) * 2024-04-08 2025-12-16 美商銳進科斯生物股份有限公司 載體化抗補體抗體與補體劑及其投與
CN119039401B (zh) * 2024-08-19 2025-04-11 广州派真生物技术有限公司 腺相关病毒突变体及其应用
WO2026047120A1 (en) * 2024-08-28 2026-03-05 Medizinische Hochschule Hannover Aav viral vectors targeting the inner ear and medical treatment of the inner ear using said vectors

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
AU6430190A (en) 1989-10-10 1991-05-16 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
CA2071867A1 (en) 1989-11-06 1991-05-07 Edith Mathiowitz Method for producing protein microspheres
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
ATE252894T1 (de) 1995-01-05 2003-11-15 Univ Michigan Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung
WO1997007788A2 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics, Inc. Composition for sustained release of an agent
US6156303A (en) * 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
MX359371B (es) 2001-11-13 2018-09-25 Univ Pennsylvania Un metodo para detectar y/o identificar secuencias del virus adeno-asociado y aislamiento de secuencias novedosas identificadas de ese modo.
PT1453547T (pt) 2001-12-17 2016-12-28 Univ Pennsylvania Sequências do vírus adeno-associado (aav) do serotipo 8, vetores contendo as mesmas, e utilizações destas
EP2345731B1 (en) 2003-09-30 2015-10-21 The Trustees of the University of Pennsylvania Adeno-associated virus (AAV) clades, sequences, vectors containing same, and uses thereof
US7183969B2 (en) 2004-12-22 2007-02-27 Raytheon Company System and technique for calibrating radar arrays
ES2525067T3 (es) 2005-04-07 2014-12-17 The Trustees Of The University Of Pennsylvania Método de incremento de la función de un vector de AAV
JP4495210B2 (ja) 2005-06-09 2010-06-30 パナソニック株式会社 振幅誤差補償装置及び直交度誤差補償装置
JP2011512156A (ja) 2008-02-19 2011-04-21 アムステルダム モレキュラー セラピューティクス ビー.ブイ. 昆虫細胞におけるパルボウイルスrep及びcapタンパク質の発現の最適化
EP2425000B1 (en) 2009-04-30 2019-02-20 The Trustees Of The University Of Pennsylvania Compositions for targeting conducting airway cells comprising adeno-associated virus constructs
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
WO2012109570A1 (en) 2011-02-10 2012-08-16 The University Of North Carolina At Chapel Hill Viral vectors with modified transduction profiles and methods of making and using the same
CN105755044A (zh) 2011-04-22 2016-07-13 加利福尼亚大学董事会 具有变异衣壳的腺相关病毒病毒体及其使用方法
ES2857773T5 (es) 2011-08-24 2024-06-04 Univ Leland Stanford Junior Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos
WO2013170078A1 (en) 2012-05-09 2013-11-14 Oregon Health & Science University Adeno associated virus plasmids and vectors
CA2905952A1 (en) 2013-03-13 2014-10-02 The Children's Hospital Of Philadelphia Adeno-associated virus vectors and methods of use thereof
MX388221B (es) 2013-04-20 2025-03-19 Res Institute At Nationwide Children´S Hospital ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.
IL297919A (en) 2013-07-22 2023-01-01 Childrens Hospital Philadelphia Variant aav and compositions, methods and uses for gene transfer to cells, organs and tissues
ES2739288T3 (es) 2013-09-13 2020-01-30 California Inst Of Techn Recuperación selectiva
CN106232618A (zh) 2013-10-11 2016-12-14 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
GB201403684D0 (en) * 2014-03-03 2014-04-16 King S College London Vector
AU2015229381B2 (en) * 2014-03-11 2019-11-07 University Of Florida Research Foundation, Inc. Use of AAV-expressed M013 protein as an anti-inflammatory therapeutic
WO2015164757A1 (en) 2014-04-25 2015-10-29 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
PL4012035T3 (pl) * 2014-09-16 2025-03-24 Genzyme Corporation Wektory wirusowe związane z adenowirusami do leczenia jaskry miocylinowej (myoc)
AU2015320694B2 (en) 2014-09-24 2021-11-11 City Of Hope Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
JP6665466B2 (ja) 2015-09-26 2020-03-13 日亜化学工業株式会社 半導体発光素子及びその製造方法
WO2017070491A1 (en) 2015-10-23 2017-04-27 Applied Genetic Technologies Corporation Ophthalmic formulations
CA3040179A1 (en) 2016-10-19 2018-04-26 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
TW202102526A (zh) * 2019-04-04 2021-01-16 美商銳進科斯生物股份有限公司 重組腺相關病毒及其用途
CA3144986A1 (en) * 2019-06-27 2020-12-30 University Of Florida Research Foundation, Incorporated Enhancing aav-mediated transduction of ocular tissues with hyaluronic acid

Similar Documents

Publication Publication Date Title
JP2023545722A5 (enExample)
Bordet et al. Ocular gene therapies in clinical practice: viral vectors and nonviral alternatives
JP2021503914A5 (enExample)
JP2022529775A5 (enExample)
JP2022141670A5 (enExample)
JP2017510296A (ja) 錐体細胞における増強された遺伝子発現のための組成物および方法
JP7842082B2 (ja) 眼疾患を処置するための組成物および方法
JP7289306B2 (ja) 網膜障害を治療するための組成物及び方法
JP2023540094A5 (enExample)
Liu et al. Gene therapy targeting glaucoma: where are we?
US20150182638A1 (en) Virus-mediated delivery of bevacizumab for therapeutic applications
JP2022522776A5 (enExample)
JP2021510301A5 (enExample)
JP2025513072A5 (enExample)
US20250170276A1 (en) Gene delivery vector for delivering human vegf receptor fusion protein and use thereof
EP4703475A1 (en) Nucleic acid encoding anti-vegf protein, polynucleotide expression cassette and recombinant adeno-associated virus
JP2022533983A5 (enExample)
CN112424368A (zh) 用于调节眼内压和颅内压的材料和方法
TW202110486A (zh) 使用糖苷水解酶改善基因療法載體向視網膜細胞的遞送
CN111705069A (zh) 一种多神经营养因子联合表达载体及其应用
CN112029773A (zh) 编码bdnf的核酸及其应用
CN115927472A (zh) 一种抗vegf抗体体内表达系统的构建和应用
JP2023548145A5 (enExample)
JP2023523211A5 (enExample)
RU2023130643A (ru) Композиции и способы для лечения заболевания глаз, ассоциированного с ангиогенезом